The oldest drug in the modern pharmacopoeia — now a hot topic for mitochondrial support, cognition, and photobiomodulation synergy. Just watch the SSRI interaction.
Methylene blue (methylthioninium chloride) is a 150-year-old synthetic dye originally developed for the textile industry. It became the first fully synthetic drug in medical use — treated malaria in the late 1800s, still prescribed today for methemoglobinemia, and currently riding a wave of interest for mitochondrial and cognitive applications.
FDA approved for methemoglobinemia and used off-label for urinary tract surgery as a visualization dye. The current nootropic / longevity use is entirely off-label, supported by a mix of decades-old basic research and newer mitochondrial studies.
FDA approved for specific indications. Off-label use is common but caution warranted due to the MAOI and SSRI interactions. Not WADA prohibited.
Methylene blue can bypass damaged complexes I/III in the mitochondrial electron transport chain, shuttling electrons directly to complex IV. Useful in mitochondrial dysfunction; this is the main longevity mechanism.
Binds and reduces NO signaling. Relevant in septic shock and hypotensive states — one clinical use is catecholamine-refractory vasoplegic shock.
At clinically used doses (1–2 mg/kg), methylene blue is a potent MAO-A and MAO-B inhibitor. This is why it interacts dangerously with SSRIs / SNRIs / MAOIs — serotonin syndrome is a documented, sometimes fatal risk.
At low concentrations, MB functions as an antioxidant; at higher concentrations, can generate ROS (paradoxical pro-oxidant effect). This biphasic behavior makes dose control important.
| Benefit | Evidence |
|---|---|
| Methemoglobinemia | FDA-approved gold standard; life-saving in acute cases |
| Mitochondrial support | In-vitro and animal studies; human data still emerging |
| Cognitive enhancement | Rodrigues et al.: low-dose MB improved memory and attention in adults in fMRI studies |
| Alzheimer’s / tau | TauRx Phase 3 trials of LMTM (a methylene blue derivative): both pivotal trials (Gauthier 2016 PMID 27863809; Wilcock 2018 TRx-237-005) missed pre-specified primary endpoints. Sponsor post-hoc subgroup re-analyses suggest a monotherapy signal, but no positive blinded primary outcome exists. |
| Septic shock | Used in ICU for vasoplegia; not first-line |
| Photobiomodulation synergy | Anecdotal pairing with red-light therapy — MB absorbs red/near-infrared wavelengths |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeLow-dose effects are reported with as little as 0.5 mg. Upper nootropic range is ~4 mg. Clinical IV dosing varies by indication: 1–2 mg/kg is the standard methemoglobinemia dose (PMID 12845393), while septic-shock protocols have used 2 mg/kg IV bolus followed by a 0.5 mg/kg/h continuous infusion for up to 48 hours (PMID 39334256). These are hospital-administered doses, not something to reproduce at home.
Industrial methylene blue contains heavy-metal contamination (chromium, mercury, etc.) unsafe for human use. Use only USP / pharmaceutical-grade product. This is the single most important safety point with MB.
The SSRI interaction is the most important thing to know about methylene blue. If you’re on any antidepressant, do NOT use MB without medical supervision.
Pre-filled with a typical Methylene Blue setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Methylene Blueis widely available as a dietary supplement. You don’t need a specialty source to get a quality product — mainstream pharmacies, health retailers, and online retailers all carry it.
StackTrax does not sell supplements and does not earn a commission on supplement purchases.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeYes — for one specific indication. Methylene blue (USP injection) is FDA approved for the treatment of methemoglobinemia at 1–2 mg/kg intravenously. It is also widely used in surgical procedures as a dye marker. Use for cognitive enhancement, anti-aging, mitochondrial support, or Alzheimer’s disease is NOT FDA approved. The HMTM (hydromethylthionine mesylate) Alzheimer’s development program by TauRx has not yet received FDA or EMA approval.
For methemoglobinemia (FDA-approved): 1–2 mg/kg IV. For community / biohacker cognitive use: 0.5–4 mg/day sublingually or orally — far below the dose used in the Rodriguez 2016 fMRI study (which used ~280 mg single oral dose, roughly 70× community microdoses). High-dose protocols (15–50 mg/day for inflammation/longevity) sit in territory where hemolysis risk and serotonin-syndrome interactions become more meaningful.
CRITICAL contraindications: (1) G6PD deficiency — methylene blue can cause severe hemolytic anemia in G6PD-deficient individuals. G6PD deficiency affects approximately 400 million people globally, highest prevalence in African, Mediterranean, Middle Eastern, and Southeast Asian ancestry. Many users do not know their status — get tested before using. (2) Anyone on serotonergic medications (SSRIs, SNRIs, MAOIs, tramadol, triptans) — methylene blue is a potent MAO inhibitor and can trigger fatal serotonin syndrome. (3) Pregnancy.
For community cognitive/microdose use: pharmaceutical-grade (USP) methylene blue diluted to ~0.5–1% solution, taken sublingually or orally. The most common approach is a tincture (10 mg/mL) — 1 drop ≈ 0.5 mg, taken in the morning. CRITICAL: do NOT use aquarium-grade or fabric-dye methylene blue — those contain heavy-metal contaminants (lead, arsenic) at levels unsafe for human consumption. USP-grade or pharmaceutical-compounded is required.
The single most-cited paper is Rodriguez 2016 (PMID 27351678) — an fMRI crossover study in 26 healthy volunteers showing approximately 7% memory-retrieval improvement after a single ~280 mg oral dose. That dose is roughly 70× higher than typical biohacker microdoses (0.5–4 mg). The microdose evidence base is essentially absent — extrapolating an acute high-dose fMRI finding to chronic low-dose use is a significant leap. Effects in low-dose users are largely subjective and not well documented.
Not specifically named on the WADA Prohibited List. As a small molecule with MAO-inhibitor activity, it could potentially be flagged under broader stimulant or MAO-inhibitor categories depending on context. Competitive athletes should verify the current-year list before use.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.